Transfusion reactions after whole blood transfusion in Norway, 2021–2024: A report from the Norwegian Hemovigilance program

These findings indicate that WB transfusion in Norway is safe. However, there are inherent risks for blood transfusion in general and also risks more specific to WB transfusion. These include the presence of red blood cell alloantibodies anti-A and anti-B combined with approximately 250 mL plasma from a single donor. Accurate and timely hemovigilance work is important to safeguard patient outcomes and provide a foundation for targeted risk mitigation strategies for WB transfusion.